133 related articles for article (PubMed ID: 6655548)
21. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations.
Ozdemir N; Ordu S; Ozkan Y
Drug Dev Ind Pharm; 2000 Aug; 26(8):857-66. PubMed ID: 10900542
[TBL] [Abstract][Full Text] [Related]
22. Diuretic effect of a combined preparation of frusemide and slow-release potassium chloride.
Davis B; Warrington SJ
Curr Med Res Opin; 1978; 5(9):739-42. PubMed ID: 738078
[TBL] [Abstract][Full Text] [Related]
23. Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.
Tuttolomondo A; Di Raimondo D; Bellia C; Clemente G; Pecoraro R; Maida C; Simonetta I; Vassallo V; Di Bona D; Gulotta E; Ciaccio M; Pinto A
PLoS One; 2016; 11(12):e0165443. PubMed ID: 27941973
[TBL] [Abstract][Full Text] [Related]
24. Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver.
Brunner G; von Bergmann K; Häcker W; von Möllendorff E
Arzneimittelforschung; 1988 Jan; 38(1A):176-9. PubMed ID: 3285830
[TBL] [Abstract][Full Text] [Related]
25. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide.
Keller E; Hoppe-Seyler G; Mumm R; Schollmeyer P
Eur J Clin Pharmacol; 1981; 20(1):27-33. PubMed ID: 7308269
[TBL] [Abstract][Full Text] [Related]
26. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.
Rasool BK; Fahmy SA; Galeel OW
Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999
[TBL] [Abstract][Full Text] [Related]
27. [Formulation and in vitro examination of furosemide-containing suppositories and preliminary experiences of their clinical use].
Regdon G; Fazekas T; Regdon G; Selmeczi B
Acta Pharm Hung; 1997 Jan; 67(1):19-23. PubMed ID: 9163255
[TBL] [Abstract][Full Text] [Related]
28. Effect of albumin-furosemide mixtures on response to furosemide in cirrhotic patients with ascites.
Brater DC; Chalasani N; Gorski JC; Horlander JC; Craven R; Hoen H; Maya J
Trans Am Clin Climatol Assoc; 2001; 112():108-15; discussion 116. PubMed ID: 11413770
[No Abstract] [Full Text] [Related]
29. Two- and three-layer tablet drug delivery systems for oral sustained release of soluble and poorly soluble drugs.
Efentakis M; Naseef H; Vlachou M
Drug Dev Ind Pharm; 2010 Aug; 36(8):903-16. PubMed ID: 20196641
[TBL] [Abstract][Full Text] [Related]
30. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.
Santos J; Planas R; Pardo A; Durández R; Cabré E; Morillas RM; Granada ML; Jiménez JA; Quintero E; Gassull MA
J Hepatol; 2003 Aug; 39(2):187-92. PubMed ID: 12873814
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics and pharmacokinetics of furosemide-retard and furosemide-retard/triamterene.
Heimsoth V; Loew D; Schuster O
Eur J Drug Metab Pharmacokinet; 1988; 13(3):161-4. PubMed ID: 3240762
[TBL] [Abstract][Full Text] [Related]
32. Bumetanide and furosemide in heart failure.
Brater DC; Day B; Burdette A; Anderson S
Kidney Int; 1984 Aug; 26(2):183-9. PubMed ID: 6503136
[TBL] [Abstract][Full Text] [Related]
33. Acute tolerance development to the diuretic effect of furosemide in the rat.
Hammarlund M; Paalzow LK
Biopharm Drug Dispos; 1985; 6(1):9-21. PubMed ID: 3986304
[TBL] [Abstract][Full Text] [Related]
34. Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide.
Knauf H; Mutschler E
Cardiology; 1994; 84 Suppl 2():87-98. PubMed ID: 7954550
[TBL] [Abstract][Full Text] [Related]
35. Furosemide kinetics in renal failure.
Tilstone WJ; Fine A
Clin Pharmacol Ther; 1978 Jun; 23(6):644-50. PubMed ID: 648078
[TBL] [Abstract][Full Text] [Related]
36. Kinetics and dynamics of furosemide and slow-acting furosemide.
Beermann B
Clin Pharmacol Ther; 1982 Nov; 32(5):584-91. PubMed ID: 7127999
[TBL] [Abstract][Full Text] [Related]
37. Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect.
Alván G; Paintaud G; Eckernäs SA; Grahnén A
Br J Clin Pharmacol; 1992 Jul; 34(1):47-52. PubMed ID: 1633067
[TBL] [Abstract][Full Text] [Related]
38. Steady-state bioavailability of two clorazepate dipotassium dosage forms.
Carrigan PJ; Chao GC; Barker WM; Hoffman DJ; Chun AH
J Clin Pharmacol; 1977 Jan; 17(1):18-28. PubMed ID: 13089
[TBL] [Abstract][Full Text] [Related]
39. Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study.
McNamara PJ; Foster TS; Digenis GA; Patel RB; Craig WA; Welling PG; Rapaka RS; Prasad VK; Shah VP
Pharm Res; 1987 Apr; 4(2):150-3. PubMed ID: 3509139
[TBL] [Abstract][Full Text] [Related]
40. Influence of hepatic insufficiency in pharmacokinetics of drugs: example for an anthranilic diuretic.
Dreux C; Passa P; Halter D
Methods Find Exp Clin Pharmacol; 1979 Dec; 1(5):289-96. PubMed ID: 552592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
